Overview

Feasibility Trial for a Right Ventricular Failure Platform Trial

Status:
RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the CRAVE feasibility trial is to assess the feasibility of conducting a larger CRAVE platform trial by performing a randomized trial of 30 participants with pulmonary hypertension and right ventricular dysfunction, comparing empagliflozin or ranolazine plus standard of care to standard of care alone.
Phase:
PHASE2
Details
Lead Sponsor:
University of Alberta
Collaborators:
Accelerating Clinical Trials Consortium
Canadian Heart Function Alliance
Ottawa Heart Institute Research Corporation
Team PHenomenal Hope
Treatments:
empagliflozin
Ranolazine